(Health Korea News / Wonjin Park) Hanmi Pharmaceutical is expected to achieve the record of being ‘No. 1 in outpatient prescription sales for 7 consecutive years.’ We are also ambitiously preparing to launch ‘Post Rosuzet’, which will continue the legend of Rosuzet, which contributed greatly to achieving this record.
At a corporate information session held on the 11th, Hanmi Pharmaceutical announced mid- to long-term plans, including the business status of the domestic business division and new product development division and future growth strategies. At the briefing session on this day, Hanmi Pharmaceutical said, “Continuing from last year, we are certain to achieve first place in not only outpatient prescription sales but also total in-hospital and outpatient prescription sales this year,” and added, “We will further strengthen our competitiveness in the prescription drug market.”
Executive Director Park Myung-hee, head of the domestic business division, said, “This year, thanks to the continued performance growth of major products such as Rosuzet and Amosartan, Hanmi Pharmaceutical ranked first in outpatient prescriptions for seven consecutive years, ranked first in domestic prescription drug distribution for four consecutive years, and ranked first among domestic pharmaceutical companies. “It is expected to set a record for the largest number of blockbuster products,” he said.
He analyzed that the domestic business division’s good performance was due to ▲ revitalization of package strategy ▲ nurturing of new products and blockbusters ▲ continuous growth of major items.
Executive Director Park said, “In addition to Rosuzet, Amosartan, and Esomezole, we achieved sales of more than 10 billion won in treatments for various diseases, including urinary products such as Palpal and Hanmi Tams, ophthalmic products such as Hyalumini, antibiotics, respiratory products, and the anticancer drug Rolontis. “This year, three more items, including Phenoside, Montezal, and Ozartan, will be added, and 25 products will become blockbusters with sales of over 10 billion won.” “It is expected that the number can increase to 30 by 2028,” he said.
Executive Director Park said the goal for the next five years is, “We will accelerate the growth of key diseases and major products and diversify our portfolio through new product launches to strengthen our market response,” adding, “We will expand our patient-centered digital healthcare business as a new growth engine to achieve growth in 2028.” “The goal is to achieve sales of 1.7 trillion won.”
Hanmi Pharmaceutical plans to continuously release highly competitive new products to further activate a virtuous cycle in which profits earned from self-developed products are invested in new drug development R&D.
Executive Director Kim Na-young, head of the New Product Development Division, said, “The ‘post-Rosujet’ candidates selected based on the successful launch experience of Rosuzet will be a low-dose combination drug for high blood pressure and efpeglenatide, which is currently undergoing clinical trials with the goal of launching in 2026.” Rosuzet is scheduled to be released within the next one to two years, and this product will further strengthen Hanmi Pharmaceutical’s position in the market.”
Hanmi Pharmaceutical predicts that innovation in the treatment of high blood pressure will come in the future, and is currently developing new improved and combined drugs for various indications such as high blood pressure, dyslipidemia, diabetes, and musculoskeletal system. In particular, the domestic phase 3 clinical trial of ‘HCP1803’, the first low-dose hypertension triple drug combination drug in the country, is progressing smoothly. The clinical trial completion point is expected to be in the second half of 2024. According to research results presented at the European Society of Hypertension (ESH) last June, HCP1803 reflects the next-generation treatment concept that low-dose combination therapy of three antihypertensive ingredients can be effective as an initial treatment for hypertension, making it the first-line treatment paradigm for hypertension. Expectations that we can change are also increasing.
Hanmi Pharmaceutical also plans to introduce a business model that combines prevention, diagnosis, and treatment with its new product R&D strategy. We are currently developing Korea’s first digital convergence medicine that combines the obesity treatment drug ‘efpeglenatide’, which is currently undergoing phase 3 clinical trials, with a digital treatment device. In the case of obesity treatment, it is important to combine diet and exercise therapy, so the plan is to maximize the weight loss effect and provide customized treatment options for patients through digital treatment devices.
Executive Director Kim said, “The new product development division should not only focus on and develop the existing large market, but become a true first mover that pioneers and leads the market by launching new products for the first time.” The proportion of sales is about 6.4%, and the rest are self-developed products. “In the future, we will continue to develop and continuously introduce an innovative product pipeline that can lead future new product trends,” he emphasized.
“We expect this corporate information session to further strengthen Hanmi’s leadership in the pharmaceutical market and serve as a stepping stone to increase competitiveness in the domestic and global markets through the launch of innovative new products,” said Park Jae-hyun, CEO of Hanmi Pharmaceuticals. “We expect this to be a stepping stone for domestic business and new product development.” “All executives and employees will work harder to achieve a super gap in the domestic market by next year and lay the foundation for entering the global market by combining , formulation research institute, and R&D fields,” he said.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
